A notable pharma stock gained attention after North Star Opportunities Fund VCC-Bull Value Incorporated VCC Sub-Fund acquired 1.5 lakh shares worth Rs.5.35 crore in a recent bulk deal. The transaction has sparked market interest, indicating growing institutional confidence in the company.
Price Action
During Thursday’s session, Sudarshan Pharma Industries Ltd’s shares are trading at Rs.34.32 apiece, slightly lower than the previous close of Rs.35.02 apiece. Over the past year, it has gained more than 400 percent.
Bulk Deal
On February 11, 2025, North Star Opportunities Fund VCC-Bull Value Incorporated VCC Sub-Fund acquired 15 lakh shares of Sudarshan Pharma Industries Ltd through a bulk deal on the BSE. The shares were purchased at Rs.35.73 apiece, reflecting strong institutional interest in the company.
Product Portfolio
Sudarshan Pharma Industries Ltd. is an India-based company focused on manufacturing and trading active pharmaceutical ingredients (APIs), pharmaceutical products, and various chemicals. Their product portfolio includes generic medicines, branded generics, and innovative drug delivery systems, alongside a wide array of chemicals catering to diverse industries.
They operate WHO, GMP, and GLP-approved manufacturing facilities, emphasizing both domestic production and international trade. The company is also expanding its API manufacturing capabilities to reduce reliance on imports.
Financial Performance
Sudarshan Pharma Industries Ltd reported revenue of Rs.225 crore in Q2 FY25, marking a 3 percent decline from Rs.232 crore in the corresponding quarter last year. Sequentially, revenue saw a 4 percent dip from Rs.234 crore in Q1 FY25.
The company’s Profit After Tax (PAT) rose 20 percent year-on-year to Rs.6 crore from Rs.5 crore in the same period. However, on a quarterly basis, PAT remained unchanged at Rs.6 crore.
Ratio Analysis
The Return on Capital Employed (ROCE) of the company stands at 12.39 percent, while the Return on Equity (ROE) is 10.65 percent.
The company’s Price-to-Earnings (P/E) ratio is 72.96, which is higher than the industry average of 45.51. Additionally, the company maintains a good current ratio of 3.32 and a debt-to-equity ratio of 1.06.
Written by – Siddesh S Raskar
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
